Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Business Wire•02/11/2026•08:30 ET
0
Key Highlights
- ➤Gilead will present results from more than 50 HIV studies at HIV Glasgow 2026
- ➤PURPOSE 5 Phase 2 data assess one-year persistence and safety of twice-yearly lenacapavir PrEP
- ➤ISLEND Phase 3 results evaluate investigational once-weekly oral islatravir/lenacapavir treatment
- ➤ARTISTRY Phase 3 data evaluate once-daily oral bictegravir/lenacapavir in people with HIV
- ➤GS-3242 Phase 1b data support development of a potential twice-yearly injectable treatment
Expert Statements
Jared Baeten, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences
“We look forward to presenting new research from our broad and innovative HIV portfolio and pipeline as we strive to help end the epidemic through continuous scientific discovery”
Jared Baeten, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences
“Our contributions to HIV Glasgow 2026 demonstrate that people are at the center of all we do at Gilead. The breadth and depth of Gilead’s work underscore our commitment to driving the next wave of transformational innovation in HIV research.”
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
– Results Highlight the Potential of Long-Acting Regimens, Including Twice-Yearly and Once-Weekly Options, to Transform the Treatment and Prevention of HIV –
Get started
Create a free account to read the full story.